Literature DB >> 7999052

Distribution of lysosomal protective protein in human tissues.

A Satake1, K Itoh, M Shimmoto, T C Saido, H Sakuraba, Y Suzuki.   

Abstract

We raised two polyclonal antibodies against synthetic oligopeptides comprising amino acid sequences in the human lysosomal protective protein. The first antibody recognized the 54-kDa precursor and the N-terminal sequence of the 32-kDa mature protein subunit, and the second one recognized the precursor and the C-terminal sequence of the 20-kDa subunit. In normal fibroblasts, mature protective protein was detected on immunoblotting with these antibodies. Considerable amounts of mature protective protein also were detected in kidney, lung, liver, and spleen, but not in brain from a patient with Gaucher disease. Neither the precursor nor the mature protective protein was detected in cultured fibroblasts, liver or cerebrum from a galactosialidosis patient with protective protein deficiency.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999052     DOI: 10.1006/bbrc.1994.2626

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620.

Authors:  Eisuke Murakami; Ting Wang; Darius Babusis; Eve-Irene Lepist; Dorothea Sauer; Yeojin Park; Jennifer E Vela; Robert Shih; Gabriel Birkus; Dimitrios Stefanidis; Choung U Kim; Aesop Cho; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

2.  Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.

Authors:  Gabriel Birkus; Ruth Wang; Xiaohong Liu; Nilima Kutty; Holly MacArthur; Tomas Cihlar; Craig Gibbs; Swami Swaminathan; William Lee; Martin McDermott
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

3.  Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.

Authors:  Mackenzie L Cottrell; Katy L Garrett; Heather M A Prince; Craig Sykes; Amanda Schauer; Cindi W Emerson; Anne Peery; James F Rooney; Scott McCallister; Cynthia Gay; Angela D M Kashuba
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

4.  Stable expression of protective protein/cathepsin A-green fluorescent protein fusion genes in a fibroblastic cell line from a galactosialidosis patient. Model system for revealing the intracellular transport of normal and mutated lysosomal enzymes.

Authors:  Y Naganawa; K Itoh; M Shimmoto; S Kamei; K Takiguchi; H Doi; H Sakuraba
Journal:  Biochem J       Date:  1999-06-01       Impact factor: 3.857

5.  Lysosomal Cathepsin A Plays a Significant Role in the Processing of Endogenous Bioactive Peptides.

Authors:  Zehra Kevser Timur; Secil Akyildiz Demir; Volkan Seyrantepe
Journal:  Front Mol Biosci       Date:  2016-10-25

Review 6.  Cathepsins in Bacteria-Macrophage Interaction: Defenders or Victims of Circumstance?

Authors:  Lidia Szulc-Dąbrowska; Magdalena Bossowska-Nowicka; Justyna Struzik; Felix N Toka
Journal:  Front Cell Infect Microbiol       Date:  2020-12-04       Impact factor: 5.293

7.  Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection.

Authors:  Jiapeng Li; Shuhan Liu; Jian Shi; Hao-Jie Zhu
Journal:  Pharmaceutics       Date:  2021-10-11       Impact factor: 6.321

8.  Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide.

Authors:  Soichiro Ito; Takeshi Hirota; Miyu Yanai; Mai Muto; Eri Watanabe; Yuki Taya; Ichiro Ieiri
Journal:  Genes (Basel)       Date:  2021-12-20       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.